Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Long-Term Investments: 2018-2025

Historic Long-Term Investments for Catalyst Pharmaceuticals (CPRX) over the last 4 years, with Sep 2025 value amounting to $19.2 million.

  • Catalyst Pharmaceuticals' Long-Term Investments rose 29.14% to $19.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.2 million, marking a year-over-year increase of 29.14%. This contributed to the annual value of $21.6 million for FY2024, which is 30.78% up from last year.
  • Catalyst Pharmaceuticals' Long-Term Investments amounted to $19.2 million in Q3 2025, which was down 9.83% from $21.3 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Long-Term Investments' 5-year high stood at $24.2 million during Q1 2025, with a 5-year trough of $12.9 million in Q3 2023.
  • Over the past 3 years, Catalyst Pharmaceuticals' median Long-Term Investments value was $16.5 million (recorded in 2023), while the average stood at $17.7 million.
  • Data for Catalyst Pharmaceuticals' Long-Term Investments shows a peak YoY spiked of 62.47% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Catalyst Pharmaceuticals' Long-Term Investments stood at $16.5 million in 2023, then spiked by 30.78% to $21.6 million in 2024, then grew by 29.14% to $19.2 million in 2025.
  • Its Long-Term Investments was $19.2 million in Q3 2025, compared to $21.3 million in Q2 2025 and $24.2 million in Q1 2025.